| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the musculoskeletal sector. The
report includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
The musculoskeletal market is the sixth largest therapeutic category by sales
and generated over US$228 billion (+0.8% YoY) in 2005. Sales grew strongly in
the US and Europe which accounted for 54% and 23% of sales however, sales have
slowed significantly, largely due to the withdrawal of a number of COX-2
inhibitors during 2004 and early 2005.
Two of the largest segments of the musculoskeletal market are rheumatoid
arthritis (anti-rheumatics) and osteoporosis (bone calcium regulators). The
remaining sales are derived from the treatment of a mixture of aetiologies
such as anti-inflammatory conditions and muscle relaxants.
TABLE OF CONTENTS
CURRENT MARKET SIZE
ANTI-RHEUMATIC DRUG SALES
ANTI-OSTEOPOROSIS DRUG SALES
ADDRESSABLE PATIENT POPULATION
- RHEUMATOID ARTHRITIS
- OSTEOPOROSIS
CURRENT TREATMENTS
- RHEUMATOID ARTHRITIS TREATMENTS
- OSTEOPOROSIS TREATMENTS
- RHEUMATOID ARTHRITIS SALES DRIVERS
- OSTEOPOROSIS SALES DRIVERS
- RHEUMATOID ARTHRITIS SALES BREAKERS
- OSTEOPOROSIS SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY DRUGS LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY MUSCULOSKELETAL DRUG LAUNCHES BY 2010
- Actemra (Roche/Chugai)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Bazedoxifene (Wyeth)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Cimzia (UCB/Celltech)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- CNTO 148 (Johnson & Johnson/Schering-Plough)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Denosumab (Amgen)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Entereg (GlaxoSmithKline/Adolor)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Febuxostat (TAP Pharmaceutical Products)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Orencia (Bristol-Myers Squibb)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Preos (NPS Pharmaceuticals)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - COMPANIES
|
